334 related articles for article (PubMed ID: 2188384)
1. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome.
Mozell E; Woltering EA; O'Dorisio TM; Fletcher WS; Sinclair AJ; Hill D
Surg Gynecol Obstet; 1990 Jun; 170(6):476-84. PubMed ID: 2188384
[TBL] [Abstract][Full Text] [Related]
2. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
3. Adult onset nesidioblastosis: response of glucose, insulin, and secondary peptides to therapy with Sandostatin.
Mozell EJ; Woltering EA; O'Dorisio TM; Phillipson BE; Fletcher J; Fletcher WS; Howe B; Hill D; Rhea D
Am J Gastroenterol; 1990 Feb; 85(2):181-8. PubMed ID: 2405644
[TBL] [Abstract][Full Text] [Related]
4. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.
Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC
Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819
[TBL] [Abstract][Full Text] [Related]
5. Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome.
Bauer FE; Hummel M; Merki HS; Schulz E; Oeder R; Marbach P
J Clin Gastroenterol; 1989 Jun; 11(3):282-6. PubMed ID: 2754214
[TBL] [Abstract][Full Text] [Related]
6. Effect of long acting somatostatin-analogue, SMS 201 995, on gut hormone secretion in normal subjects.
Kraenzlin ME; Wood SM; Neufeld M; Adrian TE; Bloom SR
Experientia; 1985 Jun; 41(6):738-40. PubMed ID: 2861106
[TBL] [Abstract][Full Text] [Related]
7. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features.
Berna MJ; Hoffmann KM; Long SH; Serrano J; Gibril F; Jensen RT
Medicine (Baltimore); 2006 Nov; 85(6):331-364. PubMed ID: 17108779
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy.
Ruszniewski P; Laucournet H; Elouaer-Blanc L; Mignon M; Bonfils S
Pancreas; 1988; 3(2):145-52. PubMed ID: 2897687
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
Vinik AI; Tsai S; Moattari AR; Cheung P
Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995).
Ellison EC; Gower WR; Elkhammas E; Woltering EA; Sparks J; O'Dorisio TM; Fabri PJ
Am J Med; 1986 Dec; 81(6B):56-64. PubMed ID: 2879448
[TBL] [Abstract][Full Text] [Related]
11. Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.
Daniels LM; Khalili M; Morano WF; Simoncini M; Mapow BC; Leaf A; Bowne WB
World J Surg Oncol; 2019 Dec; 17(1):213. PubMed ID: 31818296
[TBL] [Abstract][Full Text] [Related]
12. Abnormal pancreatic polypeptide release by secretin infusion in Zollinger-Ellison syndrome.
Rigaud D; Accary JP; Mignon M; Bonfils S
Dig Dis Sci; 1984 Aug; 29(8):696-702. PubMed ID: 6745029
[TBL] [Abstract][Full Text] [Related]
13. Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome.
Chiang HC; O'Dorisio TM; Huang SC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1990 Dec; 99(6):1565-75. PubMed ID: 2227272
[TBL] [Abstract][Full Text] [Related]
14. Studies with bombesin in the Zollinger--Ellison syndrome.
Basso N; Lezoche E; Materia A; Passaro E; Speranza V
Br J Surg; 1981 Feb; 68(2):97-100. PubMed ID: 7459630
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors.
Banasch M; Schmitz F
Wien Klin Wochenschr; 2007; 119(19-20):573-8. PubMed ID: 17985090
[TBL] [Abstract][Full Text] [Related]
16. Effect of somatostatin analogue (SMS 201-995) on molecular species of gastrin in gastrinoma.
Campagnolo D; Gower WR; Fabri PJ; Sparks J; Mekhjian HS; O'Dorisio TM; Ellison EC
Surgery; 1987 Dec; 102(6):982-7. PubMed ID: 2891204
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a human gastrinoma in nude mice.
Upp JR; Trudel JL; Townsend CM; Alexander RW; Rajaraman S; Nealon WH; Greeley GH; Thompson JC
Surgery; 1988 Dec; 104(6):1037-45. PubMed ID: 3194831
[TBL] [Abstract][Full Text] [Related]
18. Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach.
Fishbeyn VA; Norton JA; Benya RV; Pisegna JR; Venzon DJ; Metz DC; Jensen RT
Ann Intern Med; 1993 Aug; 119(3):199-206. PubMed ID: 8323088
[TBL] [Abstract][Full Text] [Related]
19. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans.
Creutzfeldt W; Lembcke B; Fölsch UR; Schleser S; Koop I
Am J Med; 1987 May; 82(5B):49-54. PubMed ID: 2884879
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
